Ewing's sarcoma

American Journal of Health-System Pharmacy

Volumn 67, Issue 19, 2010, Pages 1599-1605

  Karosas, Ann O ^a  

^a GEISINGER MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Cyclophosphamide; Epidemiology; Irinotecan; Mechanism of action; Mortality; Pediatrics; Radiation; Sarcoma; Site of action; Surgery; Temozolomide; Topotecan; Vincristine

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DASATINIB; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MELPHALAN; SOMATOMEDIN C RECEPTOR; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ANGIOGENESIS; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; EWING SARCOMA; FEVER; FLI1 GENE; FUSION GENE; HUMAN; LUNG METASTASIS; MALAISE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ADULT; BONE TUMOR; CHILD; DRUG DELIVERY SYSTEM; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; SARCOMA, EWING'S; SURVIVAL RATE; YOUNG ADULT;

EID: 79952112924     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090526     Document Type: Review

References (50)

1. Bernstein M, Heinrich K, Paulussen M et al. Ewing sarcoma family of tumors: Ewing sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG, eds. Principles and practice of pediatric oncology, 5th ed. Philadelphia: Lippincott, Williams and Wilkins; 2005:1002-32.
2. Ricchetti ET, Erol B, Stern J et al. Lower back pain and mass in a 13-year-old girl. Clin Orthop Relat Res. 2005; 430:248-57. (Pubitemid 40096160)
3. Carvajal R, Meyers P. Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am. 2005; 19:501-25. (Pubitemid 40797887)
4. Cotterill S. About James Ewing, 1866-1943. www.cancerindex.org/bone/ ewing.htm (accessed 2009 Nov 6).
5. Kretschmar CS. Ewing's sarcoma and the "peanut" tumors. N Engl J Med. 1994; 331:325-7. Editorial.
6. Iwamoto Y. Diagnosis and treatment of Ewing's sarcoma. Jpn J Clin Oncol. 2007; 37:79-89. (Pubitemid 47090704)
7. Maki RG. Pediatric sarcomas occurring in adults. J Surg Oncol. 2008; 97:360-8. (Pubitemid 351358584)
8. Cheung CC, Kandel RA, Bell RS et al. Extraskeletal Ewing sarcoma in a 77-yearold woman. Arch Pathol Lab Med. 2001; 125:1358-60. (Pubitemid 32976763)
9. Delaney TF, Hornicek FJ, Mankin MD et al. Clinical presentation, staging and prognosis of the Ewing sarcoma family of tumors. www.uptodate.com/patients/ content/topic.do?topicKey=~qUJJb5xA6pg6IO (accessed 2010 Jul 12).
10. Yock TI, Krailo M, Fryer CJ et al. Local control in pelvic Ewing sarcoma: analysis from INT-0091 - a report from the Children's Oncology Group. J Clin Oncol. 2006; 24:3838-43. [Erratum, J Clin Oncol. 2006; 24:4947.]
11. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing's sarcoma. Cancer Chemother Rep. 1962; 23:55-60.
12. Pinkel D. Cyclophosphamide in children with cancer. Cancer. 1962; 15:42-9.
13. Hustu HO, Pinkel D, Pratt CB. Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy. Cancer. 1972; 30:1522-7.
14. Rosen G, Wollner N, Tan C et al. Proceedings: disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer. 1974; 33:384-93.
15. Nesbit ME Jr, Gehan EA, Burgert EO Jr et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup Study. J Clin Oncol. 1990; 8:1664-74. (Pubitemid 20334321)
16. Evans RG, Nesbit ME, Gehan EA et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the Second Intergroup Study. J Clin Oncol. 1991; 9:1173-80.
17. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988; 61:23-32. (Pubitemid 18023106)
18. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001; 19:1818-29. (Pubitemid 32230885)
19. Kung FH, Pratt CB, Vega RA et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer. 1993; 71:1898-903. (Pubitemid 23067411)
20. Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987; 5:1191-8. (Pubitemid 18045304)
21. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348:694-701. (Pubitemid 36237038)
22. Miser JS, Krailo MD, Tarbell NJ et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol. 2004; 22:2873-6. (Pubitemid 41079906)
23. Navid F, Santana VM, Billups CA et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas. The St. Jude Children's Research Hospital experience. Cancer. 2006; 106:1846-56.
24. Womer RB, West DC, Krailo MD et al. Randomized comparison of every-twoweek v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol. 2008; 26 (May 20 suppl): 10504. Abstract.
25. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993; 11:1911-8. (Pubitemid 23304616)
26. Atra A, Whelan JS, Calvagna V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant. 1997; 20:843-6. (Pubitemid 27493921)
27. Mehta P, Wingard JR. Musculoskeletal tumors of childhood. N Engl J Med. 1999; 341:1702-3.
28. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol. 2001; 19:2812-20. (Pubitemid 32538189)
29. Barker LM, Pendergrass TW, Sanders JE et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol. 2005; 23:4354-62. (Pubitemid 46207009)
30. Fraser CJ, Weigel BJ, Perentesis JP et al. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant. 2006; 37:175-81. (Pubitemid 43108810)
31. Oberlin O, Rey A, Desfachelles AS et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Francaise des Cancers de l'Enfant. J Clin Oncol. 2006; 24:3997-4002. (Pubitemid 46630750)
32. Al-Faris N, Al Harbi T, Goia C et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr Blood Cancer. 2007; 49:190-5. (Pubitemid 47041110)
33. Yamada K, Takahaski M, Ogura M et al. High-dose chemotherapy and autologous peripheral blood stem cell transfusion for adult and adolescent patients with small round cell sarcomas. Bone Marrow Transplant. 2007; 39:471-6. (Pubitemid 46605205)
34. Snyder KM, Mackall CL. Therapy for metastatic ESFT: is it time to ask new questions? Pediatr Blood Cancer. 2007; 49:115-6. (Pubitemid 47041098)
35. Hunold A, Weddeling N, Paulussen M et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer. 2006; 47:795-800. (Pubitemid 44476756)
36. Wagner LM, McAllister N, Goldsby RE et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48:132-9. (Pubitemid 44958268)
37. Anderson P, Kopp L, Anderson N et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs. 2008; 17:1703-15.
38. Shor AC, Agreata SV, D'Amato GZ et al. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control. 2008; 15:47-54. (Pubitemid 351481991)
39. ClinicalTrials.gov. Vincristine, topotecan, and cyclophosphamide with or without bevacizumab in treating young patients with refractory or first recurrent extracranial Ewing sarcoma. http://clinicalt\rials.gov/ct/show/ NCT00516295 (accessed 2010 Aug 5).
40. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005; 315:971-9. (Pubitemid 41635382)
41. Bond M, Bernstein M, Pappo A et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008; 50:254-8.
42. Champagne MA, Capdeville R, Krailo M et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004; 104:2655-2660. (Pubitemid 39434944)
43. Shor AC, Keschman EA, Lee FY et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent or Src kinase for survival. Cancer Res. 2007; 67:2800-8. (Pubitemid 46548969)
44. ClinicalTrials.gov. Trial of dasatinib in advanced sarcomas. http://clinicaltrials.gov/ct2/show/NCT00464620 (accessed 2010 Jul 8).
45. Ahlen J, Wejde J, Brosjo O et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res. 2005; 11:206-16. (Pubitemid 40075797)
46. Scotlandi K, Manara MC, Nicoletti G et al. Antitumor activity of the insulin-like growth factor-1 receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005; 65:3868-76. (Pubitemid 40616368)
47. Mariani S. Targeting cancer cells: IGF receptor-1 kinase inhibitors. www.medscape.com (accessed 2009 May 12).
48. Children's Oncology Group. Phase II study of IMC-A12, a recombinant human monoclonal antibody to the insulin-like growth factor-I receptor in pediatric patients with recurrent/refractory solid tumors, ADVL0821. www. childrensoncologygroup.org (accessed 2009 Dec 7).
49. Clezardin P, Gligorov J, Delmas P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine. 2000; 67:22-9. (Pubitemid 30216935)
50. Ashford RU, McCloskey EV, Purohit OP et al. Ten-year follow-up of a patient with metastatic Ewing's sarcoma of the pelvis. Sarcoma. 2002; 6:131-3. (Pubitemid 36044256)